PMID- 37511255
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230801
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 14
DP  - 2023 Jul 15
TI  - Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
LID - 10.3390/ijms241411495 [doi]
LID - 11495
AB  - ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9-2.6% of patients with non 
      small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific 
      tyrosine-kinase inhibitors (TKI). Crizotinib, a first-generation TKI, was the 
      first target-therapy approved for the first-line treatment of ROS1-positive 
      NSCLC. Recently, entrectinib, a multitarget inhibitor with an anti-ROS1 activity 
      40 times more potent than crizotinib and better activity on the central nervous 
      system (CNS), received approval for treatment-naive patients. After a median 
      time-to-progression of 5.5-20 months, resistance mechanisms can occur, leading to 
      tumor progression. Therefore, newer generation TKI with greater potency and brain 
      penetration have been developed and are currently under investigation. This 
      review summarizes the current knowledge on clinicopathological characteristics of 
      ROS1-positive NSCLC and its therapeutic options.
FAU - Stanzione, Brigida
AU  - Stanzione B
AUID- ORCID: 0000-0002-0475-7399
AD  - Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 
      IRCCS, 33081 Aviano, Italy.
FAU - Del Conte, Alessandro
AU  - Del Conte A
AUID- ORCID: 0000-0003-1763-0335
AD  - Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 
      IRCCS, 33081 Aviano, Italy.
FAU - Bertoli, Elisa
AU  - Bertoli E
AD  - Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 
      IRCCS, 33081 Aviano, Italy.
AD  - Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.
FAU - De Carlo, Elisa
AU  - De Carlo E
AD  - Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 
      IRCCS, 33081 Aviano, Italy.
FAU - Revelant, Alberto
AU  - Revelant A
AUID- ORCID: 0000-0002-4505-9650
AD  - Department of Radiotherapy, Centro di Riferimento Oncologico di Aviano (CRO), 
      IRCCS, 33081 Aviano, Italy.
FAU - Spina, Michele
AU  - Spina M
AD  - Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 
      IRCCS, 33081 Aviano, Italy.
FAU - Bearz, Alessandra
AU  - Bearz A
AUID- ORCID: 0000-0003-1020-2338
AD  - Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 
      IRCCS, 33081 Aviano, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230715
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology
MH  - Crizotinib/therapeutic use
MH  - *Lung Neoplasms/drug therapy/genetics/pathology
MH  - Protein-Tyrosine Kinases/genetics
MH  - Proto-Oncogene Proteins/genetics
MH  - Gene Rearrangement
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
PMC - PMC10380455
OTO - NOTNLM
OT  - ROS1
OT  - non small cell lung cancer
OT  - target therapy
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:43
MHDA- 2023/07/31 06:42
PMCR- 2023/07/15
CRDT- 2023/07/29 01:23
PHST- 2023/06/10 00:00 [received]
PHST- 2023/07/11 00:00 [revised]
PHST- 2023/07/11 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/07/29 11:43 [pubmed]
PHST- 2023/07/29 01:23 [entrez]
PHST- 2023/07/15 00:00 [pmc-release]
AID - ijms241411495 [pii]
AID - ijms-24-11495 [pii]
AID - 10.3390/ijms241411495 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Jul 15;24(14):11495. doi: 10.3390/ijms241411495.